So hello, my name is Enrique Ocio from the University Hospital Marqués de Valdecilla in Santander in Spain. I will present here a poster about the fitness analysis or the analysis of the quadruplet with ISA VRD in transplant ineligible patients based on the frailty and the age. Frailty is based on the IMWG score. This was a post-doc analysis and it was less than two or more than two. This is based on age, based on the comorbidity index, the comorbidities and how they manage, how these patients manage based on their daily life activities. They are able to do it by their own or they need some help. So there is a questionnaire and this is how we define this frailty score. So as we know the quadruplets with anti-CD38 monoclonal antibodies for Tersomia Blenddex has now become the standard of care for most of our myeloma patients at diagnosis. And this is also true for those patients that are not candidates for autologous system cell transplantation. So they can receive four drugs. But the question here is if we can give four drugs to every patient and we have a limit based on age or based on the frailty of the general condition of the patient. That's why we did a secondary analysis, a pulled analysis of patients included in two different trials, the in-broth study that was the phase three trial with more than 200 patients and the phase one trial that was the basis for this phase three study that included 70 patients. So we have more than 300 patients included in this analysis, analyzing the outcomes based on age, less on more than 75 years old and based on frailty. What we saw is that there was all patients benefited from the ESA VRD, maybe those patients that are older than 75 have a lower response rate and particularly those that were frail. And that was also true for the PFS analysis and also the MRD negativity rate. So those patients that achieved a very deep responses with disappearance of all the tumor cells in their bone marrow. So what is the main message of this? The main message is that we can use quadruplets for the majority of patients, even those elderly and those frail, but we may have some cautious for those patients that are old and frail. So in this case, it's probably the outcomes are a bit shorter or a bit lower, a bit worse. So we have to be more careful and maybe they could benefit from triplets. But the main message is that probably the majority of our patients would also benefit from this quadruplet. In this case, isotoxin, malportes, somiplenolid, amethyst, and hexamethaxone. If our videos have helped you in any way and you're able to, please consider making a donation to help us continue this important work. Your gift will go three times as far when we reach $500,000 by the end of the year. Every contribution, big or small, makes a difference. And we're deeply grateful for your support.
HealthTree • December 20, 2025